2 Firms Lead $320M Vertex Buy Of Diabetes Treatment Co.
Vertex Pharmaceuticals Inc., repped by Skadden, plans to acquire Cooley-steered biotechnology company ViaCyte Inc. for $320 million in a merger that would unite the companies in working to find a cure...To view the full article, register now.
Already a subscriber? Click here to view full article